Skip to main content

Horizons Marijuana Life Sciences ETF(HMMJ-T)
TSX

Today's Change
Real-Time Last Update

Closing Bell: Horizons Marijuana Life Sciences ETF up on Wednesday (HMMJ)

Automated Summaries - The Globe and Mail - Wed Mar 20, 4:02PM CDT

Today during trading, Horizons Marijuana Life Sciences ETF shares closed at $9.80 after opening the day at $9.75. Intraday prices ranged from $9.66 to $9.84.

Share prices advanced 1.55 percent from the previous day's close of $9.65.

During the day across North America, the TSX Composite closed 0.11% at 21860.58, the S&P 500 closed 0.56% at 5178.51, the Dow Jones Industrial Average closed 0.83% at 39110.76 and the Nasdaq Composite closed 0.39% at 16166.79.

Horizons Marijuana Life Sciences ETF has listed on the Toronto Stock Exchange (TSX) under the ticker HMMJ.

Trading volume was 7,147 on 70 total trades. On average, Horizons Marijuana Life Sciences ETF has traded 11,758 shares in the last five days and 11,759 year-to-date.

The TSX market on the whole today saw 4,050 price advancers against 1,214 declines and 97 unchanged.

During the prior 52 weeks, HMMJ.TO has traded as high as $11.61 (September 12,2023) and low as $8.07 (October 27,2023). Moreover, in the last 12 months, Horizons Marijuana Life Sciences ETF's shares have shrunken -6.76%, while they have advanced 5.49% this year.

Following today's trading, Horizons Marijuana Life Sciences ETF has a market capitalization of $80.25 million on a float of 8,316 shares outstanding. Its annual EPS is $None.

Horizons Marijuana Life Sciences ETF is a None company headquartered in, None.

The Horizons Marijuana Life Sciences Index ETF seeks to replicate, to the extent possible, the performance of the North American Marijuana Index, net of expenses. The Index is designed to provide exposure to the performance of a basket of North American publicly listed life sciences companies with significant business activities in the marijuana industry..

Currently, Horizons Marijuana Life Sciences ETF's consensus rating is "Strong Sell" based on 0 analysts according to Zacks. Currently, there are for the stock.

AI at The Globe and Mail
This report is produced using automated technology that summarizes market data into articles for our readers. Ongoing project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities..

More from The Globe